Schizoaffective disorder is a psychological health condition that comprises principally various schizophrenia symptoms such as delusions and mood disorder symptoms like mania or depression. There are two core categories of schizoaffective disorder namely; depressive and bipolar type. They both entail some symptoms of schizophrenia. Particularly, the bipolar kind involves a series of mania and at times main depression while the depressive type involves major depressing incidents. The disorder can occur in a different sequence in various affected individuals (Vardaxi et al., 2018). Unmanaged schizoaffective ailment results in various problems functioning at different social institutions such as school and work thus causing loneliness and difficulties in maintaining social cues. Patients suffering from the disorder, therefore, require assistance and much support with everyday operations (Miller & Black, 2019). Appropriate treatment can aid in managing the complaint symptoms and advance the quality of life of the patient. Therefore, Schizoaffective disorder can be managed efficiently with prescription and psychotherapy. Co-occurring affluence use complaints are a solemn risk and demand comprehensive management.
Schizoaffective condition is amongst the most regularly misdiagnosed psychiatric illnesses in diagnosis exercise. Mostly, various patients with schizoaffective disorder are often mistakenly diagnosed initially with the bipolar condition or even schizophrenia. Since the schizoaffective disorder is less analyzed compared to the other two disorders, several interventions are derived from their treatment advances (Peterson et al.,2019). Due to interest in the consistency and convenience of the analytical measures for schizoaffective disorder, some scholars have suggested modifications, while others have recommended overall from DSM-5 to eliminate the diagnosis from the Diagnostic and Statistical Manual of Mental Disorders. In Australia, the disorder is relatively rare and has a lifespan prevalence of approximately 0.3%. The diagnostic standards for the schizoaffective condition have been rephrased and enhanced since its inclusion in the DSM, making it tough to consequently carry out suitable epidemiological analyses (Parker, 2019). Consequently, there have been no comprehensive studies concerning the epidemiology and occurrence of schizoaffective disorder. Research shows that 35% of cases transpire among the ages of 25 and 35, and it happens more often among females. The condition, therefore, occurs in approximately a third compared to schizophrenia with about 10 to 30% of inpatient admittances for fixation. The accurate pathophysiology of schizoaffective syndrome is presently unspecified (Kilic et al., 2019). Irregularities in dopamine, norepinephrine, and serotonin may be responsible for the condition. Additionally, malfunctions in white matter in several portions of the brain specifically the right lentiform nucleus, leftward sequential gyrus, and right precuneus, are correlated with schizophrenia and schizoaffective illness. Correspondingly, people with this disorder experience condensed hippocampal capacities and discrete distortions in the medial and adjacent thalamic areas (Kontis, et al., 2020). The initial step in analyzing schizoaffective disorder is acquiring an ample medical description while converging on the diagnostic principles for the condition.
The symptoms of schizoaffective disorder can be adverse and require close monitoring. Centered on the kind of mood disorder diagnosed, individuals will experience diverse indications. Individuals with the disorder encounter psychotic symptoms, such as illusions or aberrations, and symptoms of a mood illness whichever bipolar type or depressive sort. Hallucinations involve sighted or hearing things that are not present. While delusions are wrong and set perceptions that a patient embraces irrespective of the contrary suggestion. Disorganized thinking is another symptom of schizoaffective disorder. Whereby, an individual may shift very rapidly from a certain subject to another or postulate responses that are entirely discrete. Manic behavior is also an evident sign of the disorder. For instance, if a patient gets a schizoaffective disorder diagnosis of the bipolar type they will encounter thoughts of elation, dashing contemplations, amplified risky performance, and additional indications of mania. In the case of depressed mood, the individuals experience feelings of sorrow, emptiness, feelings of irrelevance, and other symptoms of depression. Other significant symptoms of schizoaffective illness include; diminished interaction and dialect, such as being inarticulate, curious or strange comportment, compromised professional, academic, and social execution. The other symptom is difficulties with handling personal care, involving hygiene and physical appearance.
Various factors intensify the risk of emerging schizoaffective disorder. Inheritances are one of the risk factors. For instance, having an intimate blood relative such as a parent or sibling with such a condition. The schizoaffective disorder mostly runs in relations. This does not imply that if an associate has an affliction, one will utterly get it. But it signifies that there is a grander chance of one contracting the ailment. The other risk factor is encountering traumatic incidents that may prompt the disorder’s indications. Traumatic trials such as a loss of a family member, divorce, or loss of a career can elicit signs or commencement of the disorder. Compelling mind fluctuating drugs, which could aggravate symptoms when an original disorder is present is a risk of schizophrenia disorder. Psychoactive drugs such as LSD have been associated with the progress of the schizoaffective condition. Brain configuration and chemistry is also significant risk factor. Since the brain utility and configuration may be diverse in methods that science is only initiating to comprehend, brain examinations are relieving to the enhancement of exploration in this area. People with schizoaffective syndrome are at an additional menace of perversity endeavors or suicidal attention, alcohol or other substance use complications, family and interpersonal divergences, social separation, anxiety syndromes, and significant health complications.
The management of schizoaffective condition classically contains both pharmacotherapy and psychotherapy treatment. Preceding the management commencement, if a patient with schizoaffective disorder is a menace to themselves or others, inpatient hospitalization ought to be contemplated; this comprises patients who are abandoning undertakings of day-to-day living or individuals who are incapacitated well beneath their standard in terms of performance. For pharmacotherapy, antipsychotics, antidepressants, and mood stabilizers are useful (Muñoz-Negro et al.,2021). Antipsychotics are expended to focus fixation and assertive comportment in schizoaffective ailment. Utmost primary and second-generation antipsychotics restrict dopamine receptors. Whereas second-generation antipsychotics have auxiliary activities on serotonin receptors. Antipsychotics incorporate but are not controlled by paliperidone risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and haloperidol. Clozapine is a deliberation for rebellious cases, ample similar to schizophrenia (Pacchiarotti et al.,2019). Mood stabilizers are effective for patients with phases of distractibility, imprudence, complexity, a flight of opinions, improved goal-oriented endeavor, reduced necessity for slumber, and that hyper-verbal fall in the bipolar specifier for schizoaffective disorder. The use of mood stabilizers is imperative if the patient has an antiquity of manic or hypomanic indications. These incorporate medicines such as lithium, valproic acid, carbamazepine, oxcarbazepine, and lamotrigine which target mood dysregulation (Assion et al., 2019). While antidepressants are used to aim depressive indications in schizoaffective disorder. Selective-serotonin reuptake inhibitors (SSRIs) are ideal due to their lesser threat to argumentative drug upshots and acceptability as equated to tricyclic antidepressants and selective norepinephrine reuptake inhibitors. SSRIs comprise fluoxetine, sertraline, citalopram, escitalopram, paroxetine, and fluvoxamine. It is fundamental to eliminate bipolar disorder before commencing an antidepressant due to the danger of aggravating a manic incidence (Lintunen et al., 2021).
The biopsychosocial approach for schizoaffective disorder management reflects the basis and progress of the condition as similarly associated with biological susceptibility while relating with collective and mental aspects such as seclusion and low self-confidence, with commended psychological intermediations concerning discrete requirements. Psychotherapy is an essential care strategy for patients with schizoaffective disorder. Just like most mental conditions, patients with schizoaffective disorder can profit from therapy (Sorensen, 2018). Treatment tactics should integrate distinct psychotherapy, family physiotherapy, and psychoeducational lineups. The intention is to progress their social proficiencies and advance cognitive execution to avert deterioration and probable rehospitalization. This management strategy involves learning about the illness, etiology, and management. Psychoeducation is a vital care design for patients with schizoaffective disorder. Psychoeducation entails offering exact, appropriate, and updated evidence to people living with the disorder as well as their occupations and family. The action, therefore, emphasizes refining perception and offering concrete care in handling the disorder. Psychoeducation incorporates shared decision-making. Shared decision-making encourages cooperation between patients and caregivers, whereby data is collective and patients are reinforced to express and attain conversant inclinations about their care (Beyer & Boazak, 2021).
Psychoeducation should include precise information about schizoaffective disorder. The content may entail various concepts such as; ways of identifying signs, the influence of the illness on real-life execution, and the prominence of treatment for ideal results. The caregiver should deliver vibrant and vital information and address the fundamentals of the vulnerability-stress model to sufficiently contemporary the necessity for treatment. Encouraging healthy routines, recognizing triggers of trauma, and problem-solving and interaction skills are equivalently significant areas of psychoeducation (Bröms et al., 2020). During the treatment plan, the caregiver should consider distinctive educational approaches for patients and their careers since they may be advantaged more from an attitude that heightens problem-solving skills and disseminates the affinity and realization of life ambitions. For careers, greater reputation may be assigned on the indications of schizoaffective disorder, with an effort on upholding acknowledgment. Healthcare benefactors should contemplate how enhanced access to psychoeducation can be stipulated typically to the patients. Prominently, all data should be precise, rational, and equalized, and, not influenced by predetermined stances and ideas of the care provider (O’Donoghue et al., 2018). Several facets can be integrated into sessions to aid accelerate shared decision-making. These involve honesty, reliance, esteem, and civility from each party. Reliability is a prerequisite from the clinician, for example, considering conduct preferences and probable side effects, as well as from the patients. For instance, patients should report symptoms or devotion. Thus, a sincere approach from the treatment team, a discernable concern for the personal attitudes, and compassionate conduct regarding distress caused by treatment or symptoms can assist institute an appropriate and trustful therapeutic ambiance even for patients with deprived comprehension (Etukudoh, 2021).
Open conversation of treatment preferences should transpire immediately when the patient is prepared, with verification recommending that an early outline of both pharmacological and psychosocial cares for the schizoaffective disorder can optimistically influence general conduct achievement and confidently enhance shared decision making. Patients should be fortified to sequence a further operational responsibility in their treatment by asking open-ended queries, taking time to contemplate their positions, authenticating their aptitude to apprehend evidence, and imparting them with self-assurance about their participation (Holt et al.,2019). Psychoeducation and a resilient patient partnership will often occur simultaneously. Thus, more active and occupied patients are predictably more knowledgeable concerning their treatment. Individual therapy is thus essential since it intends to stabilize perception progressions and advances the patient’s appreciation of the condition. The sessions emphasize daily ambitions, social skills, professional guidance, and social interfaces (Avasthi et al., 2020).
The health care providers should also family and group therapy for people close to the affected patient. Family and group therapy are vital in the care plan for the schizoaffective condition. This form of education benefits in passivity with medications and schedules and hence it aids postulate structure through the patient’s lifespan, specifying the vibrant description of the schizoaffective disorder. Compassionate group agendas can additionally assist if the patient has been in societal seclusion and stipulates a logic of collective proficiencies among the contestants. Various sensibly coordinated analyses have exhibited that patients in families who obtain this type of family therapy have improved results than patients with families who do not accept therapy, and that family associates account for less distress as well (Setiawati, & Aini, 2021).
In summation, Schizoaffective disorder is a psychological health disorder that comprises principally various schizophrenia symptoms such as illusions and mood disarray signs like mania or depression. Due to interest in the consistency and convenience of the analytical measures for schizoaffective disorder, some scholars have suggested modifications, while others have recommended overall from DSM-5 to eliminate the verdict from the Diagnostic and Statistical Manual of Mental Disorders. In Australia, the disorder is relatively rare and has a lifespan prevalence of approximately 0.3%, and occurs more often in women. Individuals with the disorder encounter psychotic symptoms, such as fantasies or delusions, and symptoms of a mood disorder whichever bipolar type or depressive sort. Inheritance, traumatic incidences, and drug and substance abuse are the major risk factors for the schizoaffective condition. The management of schizoaffective condition normally involves both pharmacotherapy and therapy treatment. Antipsychotics, antidepressants, and mood stabilizers are useful for pharmacology treatment. While individual therapy, psychoeducation, family therapy, and shared decision-making are the fundamental biopsychosocial approaches in the disorder care plan. Integration of all these aspects enhances easy management of the schizoaffective disorder by the patient, health caregiver and the family members.
References
Assion, H. J., Schweppe, A., Reinbold, H., & Frommberger, U. (2019). Pharmacological treatment for schizoaffective disorder. Der Nervenarzt, 90(1), 1-8. https://link.springer.com/article/10.1007/s00115-018-0507-3
Avasthi, A., Sahoo, S., & Grover, S. (2020). Clinical practice guidelines for cognitive behavioral therapy for psychotic disorders. Indian Journal of Psychiatry, 62(Suppl 2), S251.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001360/
Beyer, J. L., & Boazak, M. (2021). The Mental Health System: Definitions and Diagnoses. Mental Health Informatics, 55-80. https://link.springer.com/chapter/10.1007/978-3-030-70558-9_3
Bröms, G., Cahling, L., Berntsson, A., & Öhrmalm, L. (2020). Psychoeducation and motivational interviewing to reduce relapses and increase patients’ involvement in antipsychotic treatment: interventional study. BJPsych bulletin, 44(6), 265-268.https://www.cambridge.org/core/journals/bjpsych-bulletin/article/psychoeducation-and-motivational-interviewing-to-reduce-relapses-and-increase-patients-involvement-in-antipsychotic-treatment-interventional-study/558AAA24754C9CEDEC4D5D4B9532B091
Etukudoh, A. J. (2021). Reduction in Severity Symptoms Among Adult Patients with Psychosis by Psychoeducation (Doctoral dissertation, Brandman University). https://search.proquest.com/openview/bbca5033480751dab3e187842b109896/1?pq-origsite=gscholar&cbl=18750&diss=y
Holt, R. I., Gossage-Worrall, R., Hind, D., Bradburn, M. J., McCrone, P., Morris, T., … & Wright, S. (2019). Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. The British Journal of Psychiatry, 214(2), 63-73. https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/structured-lifestyle-education-for-people-with-schizophrenia-schizoaffective-disorder-and-firstepisode-psychosis-stepwise-randomised-controlled-trial/C0AD7E5F89AA2FF67BDB94627542F208
Kilic, O. H. T., Aksoy, I., Elboga, G. C., & Bulbul, F. (2019). Oxidative parameters, oxidative DNA damage, and urotensin–II in schizoaffective disorder patients. Psychiatry Clin. Psychopharmacol, 29, 151-157.https://psychiatry-psychopharmacology.com/Content/files/sayilar/17/Oxidative%20parameters%20oxidative%20DNA%20damage%20and%20urotensin%20II%20in%20schizoaffective%20disorder%20patients.pdf
Kontis, D., Theochari, E., Giannoulis, A., Louki, F., & Tsaltas, E. (2020). T92. POSSIBLE COMBINATIONS OF DSM-IV AND DSM-5 CRITERIA IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER VERSUS MAJOR DEPRESSIVE AND MANIC EPISODES. Schizophrenia Bulletin, 46(Supplement_1), S266-S267. https://academic.oup.com/schizophreniabulletin/articleabstract/46/Supplement_1/S266/5839517
Lintunen, J., Taipale, H., Tanskanen, A., Mittendorfer-Rutz, E., Tiihonen, J., & Lähteenvuo, M. (2021). Long-term real-world effectiveness of pharmacotherapies for schizoaffective disorder. Schizophrenia bulletin, 47(4), 1099-1107. https://academic.oup.com/schizophreniabulletin/article-abstract/47/4/1099/6127087
Miller, J. N., & Black, D. W. (2019). Schizoaffective disorder: A review. Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists, 31(1), 47-53. https://europepmc.org/article/med/30699217
Muñoz-Negro, J. E., Aguado Bailón, L., Calvo Rivera, P., & Cervilla, J. A. (2021). A retrospective naturalistic study on the psychopharmacological treatment of schizoaffective disorder. International Clinical Psychopharmacology, 36(5), 257-263.https://www.ingentaconnect.com/content/wk/incps/2021/00000036/00000005/art00006
O’Donoghue, E., Clark, A., Richardson, M., Hodsoll, J., Nandha, S., Morris, E., … & Jolley, S. (2018). Balancing ACT: evaluating the effectiveness of psychoeducation and Acceptance and Commitment Therapy (ACT) groups for people with bipolar disorder: study protocol for pilot randomised controlled trial. Trials, 19(1), 1-8. https://link.springer.com/article/10.1186/s13063-018-2789-y
Pacchiarotti, I., Tiihonen, J., Kotzalidis, G. D., Verdolini, N., Murru, A., Goikolea, J. M., … & Vieta, E. (2019). Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. European Neuropsychopharmacology, 29(4), 457-470.https://www.sciencedirect.com/science/article/pii/S0924977X19301609
Parker, G. (2019). How Well Does the DSM-5 Capture Schizoaffective Disorder?. The Canadian Journal of Psychiatry, 64(9), 607-610.https://journals.sagepub.com/doi/abs/10.1177/0706743719856845
Peterson, D. L., Webb, C. A., Keeley, J. W., Gaebel, W., Zielasek, J., Rebello, T. J., … & Reed, G. M. (2019). The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial. Schizophrenia Research, 208, 235-241.https://www.sciencedirect.com/science/article/pii/S0920996419300714
Setiawati, T., & Aini, S. (2021). Family Role on Schizoaffective Type Patients Treatment. Jurnal Psikiatri Surabaya, 10(2), 79-82. https://www.e-journal.unair.ac.id/JPS/article/view/22857
Sorensen, J. (2018). 21 The person with bipolar disorder: biopsychosocial approaches to relapse prevention. The Art and Science of Mental Health Nursing: Principles and Practice,326.https://books.google.com/books?hl=en&lr=&id=SsovEAAAQBAJ&oi=fnd&pg=PA326&dq=The+biopsychosocial+approach+for+schizoaffective+disorder&ots=Nl0O1mX0un&sig=RB-TeyJ328eZxVRTTinedKNaRQs
Vardaxi, C. C., Gonda, X., & Fountoulakis, K. N. (2018). Life events in schizoaffective disorder: A systematic review. Journal of Affective disorders, 227, 563-570.https://www.sciencedirect.com/science/article/pii/S0165032717316397
Essay Writing Service Features
Our Experience
No matter how complex your assignment is, we can find the right professional for your specific task. Contact Essay is an essay writing company that hires only the smartest minds to help you with your projects. Our expertise allows us to provide students with high-quality academic writing, editing & proofreading services.
Free Features
Free revision policy
$10Free bibliography & reference
$8Free title page
$8Free formatting
$8How Our Essay Writing Service Works
First, you will need to complete an order form. It's not difficult but, in case there is anything you find not to be clear, you may always call us so that we can guide you through it. On the order form, you will need to include some basic information concerning your order: subject, topic, number of pages, etc. We also encourage our clients to upload any relevant information or sources that will help.
Complete the order form
Once we have all the information and instructions that we need, we select the most suitable writer for your assignment. While everything seems to be clear, the writer, who has complete knowledge of the subject, may need clarification from you. It is at that point that you would receive a call or email from us.
Writer’s assignment
As soon as the writer has finished, it will be delivered both to the website and to your email address so that you will not miss it. If your deadline is close at hand, we will place a call to you to make sure that you receive the paper on time.
Completing the order and download